16 results about "Sodium dependent" patented technology

Described herein are methods of for treating and / or preventing Major adverse cardiovascular events (MACE). by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

Disclosed herein are methods of treating and ameliorating hyperinsulin hypoglycemia using sodium dependent glucose transporter (SGLT) 1 inhibitor compounds and compositions comprising them.

The present invention relates to a key intermediate for preparing a glucopyranosyl derivative, which is a sodium-dependent glucose transporter (SGLT) inhibitor, and a preparation method thereof. Specifically, the key intermediate provided by the present invention has stable properties, few impurities, and high optical purity (diastereoselectivity). The preparation method provided by the present invention utilizes inexpensive reagents, mild reaction conditions, does not require silica gel column chromatography purification, is simple to post-process, is easy to purify, has low equipment requirements, low production costs, and a safe and controllable process, making it suitable for industrial production.

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

Described herein are antibody-drug conjugates (ADCs) comprising an antibody construct that binds to human sodium-dependent phosphate transporter 2B (NaPi2b) conjugated to a camptothecin analog of Formula (I). The ADCs are useful as therapeutic agents, particularly in the treatment of cancer.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

Described herein are methods for treating and / or preventing a kidney disease or an associated disorder as measured by an increase in estimated glomerular filtration rate (eGFR) by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

The present invention relates to inhibitors of apical sodium-dependent bile acid transport (ASBT) for use in the treatment of kidney diseases and disorders, such as bile nephropathy. Such treatment can include reducing serum bile acid concentrations, increasing urinary bile acid concentrations, and improving hepatic and renal parameters.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

The present application relates to a kind of dsRNA of prawn SGLT1 gene and its application.The target sequence of the dsRNA is derived from the coding sequence corresponding to the transmembrane region outside loop, intracellular loop or extracellular loop of sodium-dependent glucose cotransporter SGLT1 gene coding protein.The dsRNA of prawn SGLT1 gene provides a new molecular means for preventing and controlling acute hepatopancreas necrosis disease.The dsRNA molecule can be synthesized by in vitro transcription or prokaryotic / eukaryotic expression system, and can be further constructed to contain the sequence expression cassette, recombinant vector and recombinant bacteria.The dsRNA molecule of the present application is small in molecular weight, biodegradable, and will not cause environmental pollution or drug residue, with the advantages of safety, environmental protection, high efficiency and scale production, etc., and can be used as a new biological agent or feed additive for preventing and controlling Vibrio parahaemolyticus AHPND infection.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

The present application relates to genotype and dose dependent responses to ASBTI in patients suffering from bile salt export pump deficiency. Provided herein are methods for treating or ameliorating cholestatic liver disease in a subject in need thereof. The methods comprise administering to the subject an apical sodium dependent bile acid transport inhibitor (ASBTI). The method includes determining a genotype of the subject, and predicting a response of the subject to administration of the ASBTI based on the genotype. The method further comprises determining, adjusting, or modulating a dose of the ASBTI administered to the subject based on the genotype or based on a measurement of a clinically related disease parameter.